This is clearly illustrated by reports that culture-activated T-cells from pmel mice (transgenic for TcR recognizing the melanoma-associated Ag gp100) can be given in a dose-dependent manner as adoptive therapy with vaccinia-gp100, rIL-2 and sublethal irradiation to cure normal syngeneic B6 mice of sizable established B16 melanoma challenges. The gene discussed is PMEL; the disease is melanoma.